首页   按字顺浏览 期刊浏览 卷期浏览 Oral Treatment of Pustulosis Palmo-Plantaris with a New Retinoid, Ro 10-9359
Oral Treatment of Pustulosis Palmo-Plantaris with a New Retinoid, Ro 10-9359

 

作者: T. Fredriksson,   U. Pettersson,  

 

期刊: Dermatology  (Karger Available online 1979)
卷期: Volume 158, issue 1  

页码: 60-64

 

ISSN:1018-8665

 

年代: 1979

 

DOI:10.1159/000250744

 

出版商: S. Karger AG

 

关键词: Pustulosis palmo-plantaris;Ro 10-9359;Retinoids;Oral treatment

 

数据来源: Karger

 

摘要:

Ro 10-9359 is a retl·noic acid derivative, selected for study because of a better tolerance than retinoic acid, shown in animal experiments. Earlier clinical experience has proved Ro 10–9359 to be an extremely potent antipsoriatic drug. The well-known association between psoriasis and pustulosis palmoplantaris was a motivation to evaluate Ro 10-9359 also in the last-mentioned disease, which is notoriously known to be resistant to treatment. In this study 30 patients were given either 75 mg/day of Ro 10-9359 or 200 mg twice every week according to a randomized pattern. All patients had suffered from the disease for at least 2 years without any spontaneous remission during the year preceding the trial. After a treatment period of about 2 weeks with Ro 10–9359 hyper-keratotic scales had usually disappeared, and 2 weeks later there were in general significantly less pustular lesions. The treatment continued for 8 weeks, and at this time the average reduction of the number of pustules was 80%. The daily dosage seemed to give better results and was also better tolerated than was the twice-weekly dosage. Side effects were common, but generally mild. On average, the remission lasted 1 month after cessation of the

 

点击下载:  PDF (1163KB)



返 回